Eli Lilly reported that the combination of its drugs Taltz and Zepbound demonstrated sustained efficacy after one year in clinical trial results. The company highlighted the durability of the treatment’s effects in its announcement.
Further details regarding patient outcomes or regulatory implications were not immediately available.
